IL-10R Polymorphisms Are Associated with Very-early-onset Ulcerative Colitis

Background:Interleukin-10 (IL-10) signaling genes are attractive inflammatory bowel disease (IBD) candidate genes as IL-10 restricts intestinal inflammation, IL-10 polymorphisms have been associated with IBD in genome-wide association studies, and mutations in IL-10 and IL-10 receptor (IL-10R) genes have been reported in immunodeficient children with severe infantile-onset IBD. Our objective was to determine if IL-10R polymorphisms were associated with early-onset IBD (EO-IBD) and very-early-onset IBD (VEO-IBD). Methods:Candidate-gene analysis of IL10RA and IL10RB was performed after initial sequencing of an infantile onset-IBD patient identified a novel homozygous mutation. The discovery cohort included 188 EO-IBD subjects and 188 healthy subjects. Polymorphisms associated with IBD in the discovery cohort were genotyped in an independent validation cohort of 422 EO-IBD subjects and 480 healthy subjects. Results:We identified a homozygous, splice-site point mutation in IL10RA in an infantile-onset IBD patient causing a premature stop codon (P206X) and IL-10 insensitivity. IL10RA and IL10RB sequencing in the discovery cohort identified five IL10RA polymorphisms associated with ulcerative colitis (UC) and two IL10RB polymorphisms associated with Crohn's disease (CD). Of these polymorphisms, two IL10RA single nucleotide polymorphisms, rs2228054 and rs2228055, were associated with VEO-UC in the discovery cohort and replicated in an independent validation cohort (odds ratio [OR] 3.08, combined P = 2 x 10−4; and OR 2.93, P = 6 x 10−4, respectively). Conclusions:We identified IL10RA polymorphisms that confer risk for developing VEO-UC. Additionally, we identified the first splice site mutation in IL10RA resulting in infantile-onset IBD. This study expands the phenotype of IL10RA polymorphisms to include both severe arthritis and VEO-UC.

[1]  David C Wilson,et al.  Pediatric modification of the Montreal classification for inflammatory bowel disease: The Paris classification , 2011, Inflammatory bowel diseases.

[2]  F. Rieux-Laucat,et al.  Defective IL10 Signaling Defining a Subgroup of Patients With Inflammatory Bowel Disease , 2011, The American Journal of Gastroenterology.

[3]  A. Rudensky,et al.  Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. , 2011, Immunity.

[4]  Francis J. Huber,et al.  Th17 cells express interleukin-10 receptor and are controlled by Foxp3⁻ and Foxp3+ regulatory CD4+ T cells in an interleukin-10-dependent manner. , 2011, Immunity.

[5]  Tariq Ahmad,et al.  Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47 , 2011, Nature Genetics.

[6]  Tariq Ahmad,et al.  Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci , 2010, Nature Genetics.

[7]  N. Sebire,et al.  Infant colitis—it's in the genes , 2010, The Lancet.

[8]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[9]  Johan Van Limbergen,et al.  Common variants at five new loci associated with early-onset inflammatory bowel disease , 2009, Nature Genetics.

[10]  A. Schäffer,et al.  Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. , 2009, The New England journal of medicine.

[11]  Gisen Kim,et al.  Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis , 2009, Nature Immunology.

[12]  C. Béroud,et al.  Human Splicing Finder: an online bioinformatics tool to predict splicing signals , 2009, Nucleic acids research.

[13]  D. Strachan,et al.  Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility , 2008, Nature Genetics.

[14]  Joseph T. Glessner,et al.  Loci on 20q13 and 21q22 are associated with pediatric-onset inflammatory bowel disease , 2008, Nature Genetics.

[15]  Judy H. Cho,et al.  Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease , 2008, Nature Genetics.

[16]  T. Karlsen,et al.  Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis , 2008, Nature Genetics.

[17]  J. Satsangi,et al.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. , 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[18]  R. Baldassano,et al.  Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. , 2005, The Journal of pediatrics.

[19]  B. Foxwell,et al.  Signal Transducer and Activator of Transcription 3 Is the Dominant Mediator of the Anti-Inflammatory Effects of IL-10 in Human Macrophages , 2004, The Journal of Immunology.

[20]  Ravi Sachidanandam,et al.  Intrinsic differences between authentic and cryptic 5' splice sites. , 2003, Nucleic acids research.

[21]  A. Filipovich,et al.  Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome , 2002, Journal of medical genetics.

[22]  S. Henikoff,et al.  Predicting deleterious amino acid substitutions. , 2001, Genome research.

[23]  R. Coffman,et al.  Interleukin-10 and the interleukin-10 receptor. , 2001, Annual review of immunology.

[24]  Susan D. Spencer,et al.  The Orphan Receptor CRF2-4 Is an Essential Subunit of the Interleukin 10 Receptor , 1998, The Journal of experimental medicine.

[25]  K. Rajewsky,et al.  Interleukin-10-deficient mice develop chronic enterocolitis , 1993, Cell.

[26]  V. Godfrey,et al.  X-linked lymphoreticular disease in the scurfy (sf) mutant mouse. , 1991, The American journal of pathology.